Can a triple strike of radiation, targeted therapy, and immunotherapy tame metastatic kidney cancer?

This phase II trial is testing whether combining precise, high-dose radiation (SABR) with the targeted drug axitinib and the immunotherapy toripalimab can shrink or control tumors in people with oligometastatic clear cell renal cell carcinoma—kidney cancer that has spread to five or fewer sites. About 48 participants will receive SABR to all metastatic lesions, along with daily axitinib pills and toripalimab infusions every three weeks for up to two years. The main goal is to measure how many patients see their tumors shrink or disappear, while also tracking survival, side effects, and quality of life.